23 results on '"Mirabelli, E"'
Search Results
2. Realistic Field Theories on Submanifolds of Compact Extra Dimensions
- Author
-
Mirabelli, E, primary
- Published
- 2005
- Full Text
- View/download PDF
3. Anatomia della cornea
- Author
-
Micali, Antonio Girolamo, Mirabelli, E, and Fragale, D.
- Subjects
ultrastruttura ,cornea ,struttura - Published
- 2007
4. MicroRNAs and cancer stem cells: the sword and the shield
- Author
-
Sun, X, primary, Jiao, X, additional, Pestell, T G, additional, Fan, C, additional, Qin, S, additional, Mirabelli, E, additional, Ren, H, additional, and Pestell, R G, additional
- Published
- 2013
- Full Text
- View/download PDF
5. INFLUENCE OF FERTILISATION ON THE PRODUCTION AND VITAMIN C AND SUGAR CONTENT OF "CHERRY" TOMATOES
- Author
-
Premuzic, Z., primary, de los Ríos, A., additional, Clozza, M., additional, Vilella, F., additional, Mirabelli, E., additional, and Accorinti, C., additional
- Published
- 2001
- Full Text
- View/download PDF
6. Oh, My Beautiful Alba
- Author
-
Mirabelli, Eugene
- Published
- 2016
- Full Text
- View/download PDF
7. In situ laser light scattering for monitoring III-V semiconductor film growth by molecular-beam epitaxy.
- Author
-
Yang, K., Mirabelli, E., Wu, Z.-C., and Schowalter, L. J.
- Published
- 1993
- Full Text
- View/download PDF
8. Discussion of “Mirabelli on Steel and Light-Weight Alloys”
- Author
-
Mirabelli, E., primary, Vose, R. W., additional, Hobrock, Raymond H., additional, Clapp, William F., additional, Hunsaker, J. C., additional, Knerr, Horace C., additional, Sisco, F. T., additional, Rathbun, J. Charles, additional, MacAlpine, D. M., additional, Plummer, Fred L., additional, Goodrich, C. F., additional, Herzog, G. K., additional, Meursinge, John H., additional, Lang, P. G., additional, Warner, W. L., additional, Timby, Elmer K., additional, Lehman, Werner, additional, Hovey, Otis E., additional, Sturm, R. G., additional, DeLuccia, E. Robert, additional, Horger, O. J., additional, Demmler, A. W., additional, Belzner, Theodore, additional, Growdon, J. P., additional, Arnstein, Karl, additional, Christianson, A., additional, Glover, Robert E., additional, Ruge, Arthur C., additional, Klemin, Alexander, additional, Gisiger, Paul E., additional, Brinker, Russell C., additional, Solakian, Arshag G., additional, Hussey, H. D., additional, Freeman, Ralph, additional, Karpov, A. V., additional, Moisseiff, Leon S., additional, Templin, R. L., additional, Brahtz, J. H. A., additional, Morris, M. J. R., additional, Jeffries, Zay, additional, Nagel, C. F., additional, Wood, R. T., additional, Aston, James, additional, and Hartmann, E. C., additional
- Published
- 1937
- Full Text
- View/download PDF
9. Discussion of “Mirabelli on Experiments with Concrete in Torsion”
- Author
-
Mirabelli, E., primary, Russell, Frank M., additional, Turner, Leslie, additional, Fischer, A. W., additional, Gilkey, H. J., additional, and Eremin, A. A., additional
- Published
- 1935
- Full Text
- View/download PDF
10. Discussion of “Morris on Moment of Inertia of Girder”
- Author
-
Osgood, William R., primary, Morris, Clyde T., additional, Leffler, B. R., additional, Lane, E. Neil W., additional, Moore, Lewis E., additional, Black, W. E., additional, Grinter, L. E., additional, Spofford, Charles M., additional, Mirabelli, E., additional, Godfrey, Edward, additional, Weiskopf, Walter H., additional, Williams, C. D., additional, Auerbach, Alvin B., additional, Jones, Jonathan, additional, Moore, R. L., additional, Garrelts, J. M., additional, Madsen, I. E., additional, Witmer, Francis P., additional, Fischer, A. W., additional, Shank, J. R., additional, Hussey, Harold D., additional, Kring, Charles U., additional, and Shedd, Thomas C., additional
- Published
- 1940
- Full Text
- View/download PDF
11. Discussion of “Hall on Panel Deflection Method”
- Author
-
Hall, David B., primary, Mirabelli, E., additional, Bertwell, William, additional, Hurlbutt, Robert H., additional, Eremin, A. A., additional, Noe, T. P., additional, Molitor, David A., additional, Enke, Glenn L., additional, Tsai, Fang-Yin, additional, Fischer, A. W., additional, and Grinter, L. E., additional
- Published
- 1937
- Full Text
- View/download PDF
12. Discussion of “Meursinge on Theory of Limit Design”
- Author
-
Meursinge, John H., primary, Silverman, I. K., additional, Godfrey, Edward, additional, Sourochnikoff, Basil, additional, Mirabelli, E., additional, Goodrich, C. M., additional, Winter, George, additional, Simpson, Francis E., additional, Wise, Joseph A., additional, Freudenthal, Alfred, additional, Bleich, Hans H., additional, Niles, Alfred S., additional, Floris, A., additional, Nishkian, L. H., additional, Eric Peterson, F. G., additional, Fabian, E. S., additional, Eremin, A. A., additional, and Donnell, L. H., additional
- Published
- 1940
- Full Text
- View/download PDF
13. Discussion of “Goodwin on Elastic Properties of Riveted Connections”
- Author
-
Goodwin, Ralph E., primary, Rowan, Harold C., additional, Schultz, Walter, additional, Baker, J. F., additional, Grinter, L. E., additional, Young, C. R., additional, Jackson, K. B., additional, Mirabelli, E., additional, Moore, R. L., additional, and Peck, John Sanford, additional
- Published
- 1936
- Full Text
- View/download PDF
14. Realistic Field Theories on Submanifolds of Compact Extra Dimensions
- Author
-
Mirabelli, E
- Published
- 2005
- Full Text
- View/download PDF
15. Cypin Inhibition as a Therapeutic Approach to Treat Spinal Cord Injury-Induced Mechanical Pain.
- Author
-
Singh NK, Gandu SR, Li L, Ni L, Acioglu C, Mirabelli E, Hiester LL, Elkabes S, and Firestein BL
- Subjects
- Mice, Female, Animals, Hyperalgesia metabolism, Neurons metabolism, Purines, Spinal Cord metabolism, Spinal Cord Injuries complications, Spinal Cord Injuries drug therapy, Spinal Cord Injuries pathology, Neuralgia drug therapy, Neuralgia etiology, Neuralgia metabolism
- Abstract
Cypin (cytosolic postsynaptic density protein 95 interactor) is the primary guanine deaminase in the central nervous system (CNS), promoting the metabolism of guanine to xanthine, an important reaction in the purine salvage pathway. Activation of the purine salvage pathway leads to the production of uric acid (UA). UA has paradoxical effects, specifically in the context of CNS injury as it confers neuroprotection, but it also promotes pain. Since neuropathic pain is a comorbidity associated with spinal cord injury (SCI), we postulated that small molecule cypin inhibitor B9 treatment could attenuate SCI-induced neuropathic pain, potentially by interfering with UA production. However, we also considered that this treatment could hinder the neuroprotective effects of UA and, in doing so, exacerbate SCI outcomes. To address our hypothesis, we induced a moderate midthoracic contusion SCI in female mice and assessed whether transient intrathecal administration of B9, starting at 1 d postinjury (dpi) until 7 dpi, attenuates mechanical pain in hindlimbs at 3 weeks pi. We also evaluated the effects of B9 on the spontaneous recovery of locomotor function. We found that B9 alleviates mechanical pain but does not affect locomotor function. Importantly, B9 does not exacerbate lesion volume at the epicenter. In accordance with these findings, B9 does not aggravate glutamate-induced excitotoxic death of SC neurons in vitro. Moreover, SCI-induced increased astrocyte reactivity at the glial scar is not altered by B9 treatment. Our data suggest that B9 treatment reduces mechanical pain without exerting major detrimental effects following SCI., Competing Interests: The authors declare no competing financial interests., (Copyright © 2024 Singh et al.)
- Published
- 2024
- Full Text
- View/download PDF
16. Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southern Italy.
- Author
-
Scondotto G, Sultana J, Vadalà M, Avitabile T, Cillino S, Foti SS, Labbate L, Longo A, Mirabelli E, Puzo MR, Rapisarda C, Ibanez Toro P, Trombetta CJ, Trifirò G, and Virgili G
- Subjects
- Aged, Aged, 80 and over, Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Dexamethasone therapeutic use, Female, Humans, Intravitreal Injections, Male, Middle Aged, Prospective Studies, Ranibizumab therapeutic use, Vascular Endothelial Growth Factor A, Macular Degeneration drug therapy, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Retinal Diseases drug therapy, Retinal Vein Occlusion diagnosis, Retinal Vein Occlusion drug therapy
- Abstract
Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on visual acuity and other ophthalmic parameters from baseline at different follow-up times for each indication. Data from 1327 patients was collected. Most patients were diagnosed with age-related macular degeneration (AMD) (660, 49.7%), followed by diabetic macular oedema (423, 31.9%), retinal vein occlusion (164, 12.3%), and myopic choroidal neovascularization (80, 6.0%). Patients were followed for a median of 10.3 months (interquartile range: 3.6 - 24.7 months). Mean patient age was 69.7 (±10.9) years and 54.2% were males. Ranibizumab (55.4%) and aflibercept (27.5%) were the most commonly used drugs. Baseline visual acuity significantly improved by about 0.05 to 0.1 logMAR at all follow-up times for AMD and RVO but less consistently for the other diseases. Intravitreal ranibizumab use accounted for half of all treatment for retinal diseases in a Southern Italian out-patient setting. Patients treated with anti-VEGF drugs for AMD and RVO in Southern Italy experienced significant improvement in VA.
- Published
- 2022
- Full Text
- View/download PDF
17. Neuropathic Pain in Multiple Sclerosis and Its Animal Models: Focus on Mechanisms, Knowledge Gaps and Future Directions.
- Author
-
Mirabelli E and Elkabes S
- Abstract
Multiple sclerosis (MS) is a multifaceted, complex and chronic neurological disease that leads to motor, sensory and cognitive deficits. MS symptoms are unpredictable and exceedingly variable. Pain is a frequent symptom of MS and manifests as nociceptive or neuropathic pain, even at early disease stages. Neuropathic pain is one of the most debilitating symptoms that reduces quality of life and interferes with daily activities, particularly because conventional pharmacotherapies do not adequately alleviate neuropathic pain. Despite advances, the mechanisms underlying neuropathic pain in MS remain elusive. The majority of the studies investigating the pathophysiology of MS-associated neuropathic pain have been performed in animal models that replicate some of the clinical and neuropathological features of MS. Experimental autoimmune encephalomyelitis (EAE) is one of the best-characterized and most commonly used animal models of MS. As in the case of individuals with MS, rodents affected by EAE manifest increased sensitivity to pain which can be assessed by well-established assays. Investigations on EAE provided valuable insights into the pathophysiology of neuropathic pain. Nevertheless, additional investigations are warranted to better understand the events that lead to the onset and maintenance of neuropathic pain in order to identify targets that can facilitate the development of more effective therapeutic interventions. The goal of the present review is to provide an overview of several mechanisms implicated in neuropathic pain in EAE by summarizing published reports. We discuss current knowledge gaps and future research directions, especially based on information obtained by use of other animal models of neuropathic pain such as nerve injury., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Mirabelli and Elkabes.)
- Published
- 2021
- Full Text
- View/download PDF
18. How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010-2016.
- Author
-
Scondotto G, Sultana J, Ientile V, Ingrasciotta Y, Fontana A, Copetti M, Mirabelli E, Trombetta CJ, Rapisarda C, Reibaldi M, Avitabile T, Longo A, Toro PI, Vadalà M, Cillino S, Virgili G, Gini R, Leoni O, Pollina Addario SW, Cananzi P, La Cavera C, Puzo MR, De Sarro G, De Francesco A, and Trifirò G
- Subjects
- Aged, Aged, 80 and over, Diabetic Retinopathy epidemiology, Drug Implants administration & dosage, Female, Humans, Insurance Claim Review, Italy epidemiology, Macular Edema epidemiology, Male, Middle Aged, Angiogenesis Inhibitors administration & dosage, Dexamethasone administration & dosage, Diabetic Retinopathy drug therapy, Macular Edema drug therapy, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Purpose: To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions., Methods: Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data., Results: Overall, 41,836 patients received ≥1 study drug in 2010-2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0.2 (Basilicata) to 1.4 (Lombardy) per 10,000 persons. Overall, 40,815 persons were incident users of study drugs. Among incident users with ≥1 year of follow-up ( N = 30,745), 16.0% ( N = 30,745), 16.0% ( N = 30,745), 16.0% (., Conclusion: Study drug use increased over time in Lombardy, Basilicata, Calabria, and Sicily, despite a large heterogeneity in prevalence of use across regions. Drug treatment appeared to be partly in line with SPC, suggesting that improvement in clinical practice may be needed to maximize drug benefits., Competing Interests: Giulia Scondotto, Janet Sultana, Valentina Ientile, Ylenia Ingrasciotta, Andrea Fontana, Massimiliano Copetti, Eliana Mirabelli, Costantino J. Trombetta, Carlo Rapisarda, Teresio Avitabile, Antonio Longo, Patricia Ibanez Toro, Maria Vadalà, Salvatore Cillino, Gianni Virgili, Olivia Leoni, Sebastiano Walter Pollina Addario, Pasquale Cananzi, Claudia La Cavera, Maria Rosalia Puzo, Giovambattista De Sarro, Adele De Francesco have no conflicts of interest to declare. Gianluca Trifirò participated in advisory boards within the last five years on topics not related to this manuscript and organized by Sandoz, Hospira, Sanofi, Biogen, Ipsen, and Shire and is a consultant for Otsuka. He is the principal investigator of observational studies funded by several pharmaceutical companies (e.g., Amgen, AstraZeneca, Daiichi Sankyo, IBSA) to the University of Messina as well as scientific coordinator of the master's program “Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real world data evaluations” at the University of Messina which receives unconditional funding from several pharmaceutical companies., (Copyright © 2020 Giulia Scondotto et al.)
- Published
- 2020
- Full Text
- View/download PDF
19. Pathological pain processing in mouse models of multiple sclerosis and spinal cord injury: contribution of plasma membrane calcium ATPase 2 (PMCA2).
- Author
-
Mirabelli E, Ni L, Li L, Acioglu C, Heary RF, and Elkabes S
- Subjects
- Animals, Disease Models, Animal, Female, Male, Mice, Mice, Inbred C57BL, Multiple Sclerosis metabolism, Pain Perception physiology, Spinal Cord Dorsal Horn metabolism, Encephalomyelitis, Autoimmune, Experimental metabolism, Neuralgia metabolism, Plasma Membrane Calcium-Transporting ATPases metabolism, Spinal Cord Injuries metabolism
- Abstract
Background: Neuropathic pain is often observed in individuals with multiple sclerosis (MS) and spinal cord injury (SCI) and is not adequately alleviated by current pharmacotherapies. A better understanding of underlying mechanisms could facilitate the discovery of novel targets for therapeutic interventions. We previously reported that decreased plasma membrane calcium ATPase 2 (PMCA2) expression in the dorsal horn (DH) of healthy PMCA2
+/- mice is paralleled by increased sensitivity to evoked nociceptive pain. These studies suggested that PMCA2, a calcium extrusion pump expressed in spinal cord neurons, plays a role in pain mechanisms. However, the contribution of PMCA2 to neuropathic pain processing remains undefined. The present studies investigated the role of PMCA2 in neuropathic pain processing in the DH of wild-type mice affected by experimental autoimmune encephalomyelitis (EAE), an animal model of MS, and following SCI., Methods: EAE was induced in female and male C57Bl/6N mice via inoculation with myelin oligodendrocyte glycoprotein fragment 35-55 (MOG35-55 ) emulsified in Complete Freund's Adjuvant (CFA). CFA-inoculated mice were used as controls. A severe SC contusion injury was induced at thoracic (T8) level in female C57Bl/6N mice. Pain was evaluated by the Hargreaves and von Frey filament tests. PMCA2 levels in the lumbar DH were analyzed by Western blotting. The effectors that decrease PMCA2 expression were identified in SC neuronal cultures., Results: Increased pain in EAE and SCI was paralleled by a significant decrease in PMCA2 levels in the DH. In contrast, PMCA2 levels remained unaltered in the DH of mice with EAE that manifested motor deficits but not increased pain. Interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), and IL-6 expression were robustly increased in the DH of mice with EAE manifesting pain, whereas these cytokines showed a modest increase or no change in mice with EAE in the absence of pain. Only IL-1β decreased PMCA2 levels in pure SC neuronal cultures through direct actions., Conclusions: PMCA2 is a contributor to neuropathic pain mechanisms in the DH. A decrease in PMCA2 in DH neurons is paralleled by increased pain sensitivity, most likely through perturbations in calcium signaling. Interleukin-1β is one of the effectors that downregulates PMCA2 by acting directly on neurons.- Published
- 2019
- Full Text
- View/download PDF
20. Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.
- Author
-
Trifirò G, Marcianò I, Cutroneo PM, Spina E, Mirabelli E, Trombetta CJ, and Morgante F
- Abstract
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and reinstatement of visual acuity. In May 2015, symptomatic relapse was detected. The patient was again treated with intravitreal ranibizumab, with overall six injections till the end of February 2016. In May 2016, the patient complained of left hand resting tremor, bradykinesia, and postural rigidity of head and trunk. A diagnosis of clinically established PD was made based on new criteria of the Movement Disorders Society. Single Photon Emission Computerized Tomography of the Dopamine Transporter with (123I) ioflupane documented a low Dopamine Transporter (DAT) uptake mostly in the right striatum. Due to the documented protective role of vascular endothelial growth factor (VEGF) on the dopaminergic neurons, intensive intravitreal injections of the anti-VEGF agent ranibizumab may have played as an additional risk factor accelerating the neurodegeneration process related to PD and the onset of the related clinical signs and symptoms.
- Published
- 2018
- Full Text
- View/download PDF
21. A toll-like receptor 9 antagonist restores below-level glial glutamate transporter expression in the dorsal horn following spinal cord injury.
- Author
-
Pallottie A, Ratnayake A, Ni L, Acioglu C, Li L, Mirabelli E, Heary RF, and Elkabes S
- Subjects
- Animals, Astrocytes pathology, Female, Mice, Microglia pathology, Spinal Cord Dorsal Horn pathology, Spinal Cord Injuries drug therapy, Spinal Cord Injuries pathology, Toll-Like Receptor 9 metabolism, Amino Acid Transport System X-AG biosynthesis, Astrocytes metabolism, Microglia metabolism, Oligodeoxyribonucleotides pharmacology, Spinal Cord Dorsal Horn metabolism, Spinal Cord Injuries metabolism, Toll-Like Receptor 9 antagonists & inhibitors
- Abstract
Spinal cord (SC) trauma elicits pathological changes at the primary lesion and in regions distant from the injury epicenter. Therapeutic agents that target mechanisms at the injury site are likely to exert additional effects in these remote regions. We previously reported that a toll-like receptor 9 (TLR9) antagonist, oligodeoxynucleotide 2088 (ODN 2088), improves functional deficits and modulates the milieu at the epicenter in mice sustaining a mid-thoracic contusion. The present investigations use the same paradigm to assess ODN 2088-elicited alterations in the lumbar dorsal horn (LDH), a region remote from the injury site where SCI-induced molecular alterations have been well defined. We report that ODN 2088 counteracts the SCI-elicited decrease in glial glutamate aspartate transporter (GLAST) and glutamate transporter 1 (GLT1) levels, whereas the levels of the neuronal glutamate transporter excitatory amino acid carrier 1 (EAAC1) and astroglial GABA transporter 3 (GAT3) were unaffected. The restoration of GLAST and GLT1 was neither paralleled by a global effect on astrocyte and microglia activation nor by changes in the expression of cytokines and growth factors reported to regulate these transporters. We conclude that the effects of intrathecal ODN 2088 treatment extend to loci beyond the epicenter by selectively targeting glial glutamate transporters.
- Published
- 2018
- Full Text
- View/download PDF
22. Toll like receptor 9 antagonism modulates spinal cord neuronal function and survival: Direct versus astrocyte-mediated mechanisms.
- Author
-
Acioglu C, Mirabelli E, Baykal AT, Ni L, Ratnayake A, Heary RF, and Elkabes S
- Subjects
- Animals, Cells, Cultured, Cytosine Nucleotides pharmacology, Female, Guanosine pharmacology, Mice, Mice, Inbred C57BL, Mice, Knockout, Oligodeoxyribonucleotides pharmacology, Pregnancy, Astrocytes drug effects, Endoplasmic Reticulum Stress drug effects, Neurons drug effects, Neuroprotective Agents pharmacology, Spinal Cord drug effects, Toll-Like Receptor 9 antagonists & inhibitors
- Abstract
Toll like receptors (TLRs) are expressed by cells of the immune system and mediate the host innate immune responses to pathogens. However, increasing evidence indicates that they are important contributors to central nervous system (CNS) function in health and in pathological conditions involving sterile inflammation. In agreement with this idea, we have previously shown that intrathecal administration of a TLR9 antagonist, cytidine-phosphate-guanosine oligodeoxynucleotide 2088 (CpG ODN 2088), ameliorates the outcomes of spinal cord injury (SCI). Although these earlier studies showed a marked effect of CpG ODN 2088 on inflammatory cells, the expression of TLR9 in spinal cord (SC) neurons and astrocytes suggested that the antagonist exerts additional effects through direct actions on these cells. The current study was undertaken to assess the direct effects of CpG ODN 2088 on SC neurons, astrocytes and astrocyte-neuron interactions, in vitro. We report, for the first time, that inhibition of TLR9 in cultured SC neurons alters their function and confers protection against kainic acid (KA)-induced excitotoxic death. Moreover, the TLR9 antagonist attenuated the KA-elicited endoplasmic reticulum (ER) stress response in neurons, in vitro. CpG ODN 2088 also reduced the transcript levels and release of chemokine (C-X-C) motif ligand 1 (CXCL1) and monocyte chemotactic protein 1 (MCP-1) by astrocytes and it diminished interleukin-6 (IL-6) release without affecting transcript levels in vitro. Conditioned medium (CM) of CpG ODN 2088-treated astroglial cultures decreased the viability of SC neurons compared to CM of vehicle-treated astrocytes. However, this toxicity was not observed when astrocytes were co-cultured with neurons. Although CpG ODN 2088 limited the survival-promoting effects of astroglia, it did not reduce neuronal viability compared to controls grown in the absence of astrocytes. We conclude that the TLR9 antagonist acts directly on both SC neurons and astrocytes. Neuronal TLR9 antagonism confers protection against excitotoxic death. It is likely that this neuroprotection is partly due to the attenuation of the ER stress response provoked by excitotoxicity. Although CpG ODN 2088 limits the supportive effects of astrocytes on neurons, it could potentially exert beneficial effects by decreasing the release of pro-inflammatory cytokines and chemokines by astroglia. These findings highlight the multiple roles of TLR9 in the SC and have implications for pathological conditions including SCI where excitotoxicity and neuroinflammation play a prominent role in neuronal degeneration., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
23. One year outcome of manual alcohol-assisted removal of Salzmann's nodular degeneration.
- Author
-
Roszkowska AM, Colosi P, De Grazia L, Mirabelli E, and Romeo G
- Subjects
- Administration, Topical, Adult, Corneal Diseases diagnosis, Corneal Diseases physiopathology, Corneal Topography, Follow-Up Studies, Humans, Male, Treatment Outcome, Visual Acuity, Corneal Diseases drug therapy, Corneal Diseases surgery, Ethanol administration & dosage
- Abstract
Background: To analyze visual and refractive modifications and corneal topography changes in a patient treated for bilateral advanced Salzmann's nodular degeneration (SND)., Methods: A forty-three-year-old man with bilateral advanced SND underwent manual, alcohol-assisted removal of the altered layer. Visual acuity, refraction, corneal topography and corneal aberrations were examined before and after the treatment after 7 days and 1, 6 and 12 months., Results: The uncorrected visual acuity changed from 0.1 to 1.0 in both eyes. Refraction changed from sphere +3.00 and cylinder +4.50 x 180 degrees in the right eye and sphere +6 and cylinder +4.0 x 170 degrees in the left eye to bilateral emetropia. Corneal topography recovered from an extremely flat profile to a normal shape and it was unvaried during the follow-up period. Main topographic indices, highly altered before the treatment, normalized and were normal at control examinations. The quality of vision improved significantly with reduction of high-order aberrations from RMS of 5,07 microm to 0,66 microm in the right eye and RMS of 4,89 microm to 0,57 microm in the left eye respectively., Conclusions: Salzmann nodules produce an impressive central corneal flattening with high hyperopic refractive error and significant increment of corneal aberrations. After manual removal of the altered layer, the visual and refractive recovery, corneal topography and aberrometry normalization were immediate and stable during the observational period.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.